Please Wait.....
Report
Middle East and Africa Genetic Testing Market - Industry Trends and Forecast to 2029
Market Report I 2022-11-01 I 222 Pages I Data Bridge Market Research
Middle East and Africa genetic testing market is projected to register a substantial CAGR of 13.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Middle East and Africa Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive and Presymptomatic Testing, Prenatal Testing, Other Types ), Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Reproductive Genetic Testing, Health & Wellness Genetic Testing, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories) Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast To 2030
Some of the major factors contributing to the growth of the Middle East and Africa genetic testing market are:
- Increase in the adoption of next-generation sequencing
- Technological advancement in genetic testing
Market Players:
Some of the key market players for the Middle East Africa genetic testing market are listed below:
- Abbott
- 23ANDME,Inc
- Danaher
- Myriad Genetics, Inc.
- OCP Medical Centre, L.L.C
- Healthchecks360
- Bayer AG
- BioReference Health, LLC (a subsidiary of OPKO Health, Inc.)
- FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C).
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Biocartis
- Eurofins Scientific
- PerkinElmer Inc.
- ELITechGroup
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- QIAGEN
- BIO-HELIX
- PacBio
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET 24
1.4 LIMITATIONS 26
1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET APPLICATION COVERAGE GRID 38
2.11 SECONDARY SOURCES 39
2.12 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 43
4.1 PESTEL ANALYSIS 44
4.2 PORTER'S FIVE FORCES 45
4.3 STRATEGIC INITIATIVES: 46
4.4 INDUSTRY INSIGHTS 48
4.4.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING IN MIDDLE EAST AND AFRICA 48
4.4.2 GENETIC TESTS PRICING 48
4.4.3 KEY INSIGHTS 49
5 EPIDEMIOLOGY 50
6 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: REGULATIONS 51
7 MARKET OVERVIEW 53
7.1 DRIVERS 55
7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 55
7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 55
7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER 56
7.1.4 INCREASE TREND TOWARDS PERSONALIZED MEDICATION 56
8.1 RESTRAINT 58
8.1.1 HIGH COST OF GENETIC TESTING 58
8.1.2 CYBER SECURITY CONCERN IN GENOMICS 58
8.2 OPPORTUNITIES 59
8.2.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 59
8.2.2 TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 59
8.2.3 INCREASING RESEARCH AND DEVELOPMENT 60
8.2.4 RISING DISPOSABLE INCOME 61
8.3 CHALLENGES 62
8.3.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 62
8.3.2 STRINGENT REGULATION POLICY 62
9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE 64
9.1 OVERVIEW 65
9.2 DIAGNOSTIC TESTING 68
9.3 PRENATAL TESTING 69
9.3.1 NON-INVASIVE SCREENING 70
9.3.1.1 BY SCREENING METHOD 70
9.3.1.2 WHOLE GENOME SEQUENCING 71
9.3.1.3 COUNTING OF CFDNA FRAGMENTS 71
9.3.1.4 OTHERS 71
9.3.1.5 BY CONDITION 72
9.3.1.5.1 TRISOMY 21 72
9.3.1.5.2 KLINEFELTER SYNDROME 72
9.3.1.5.3 JACOBS SYNDROME 72
9.3.1.5.4 CYSTIC FIBROSIS 72
9.3.1.5.5 TURNER SYNDROME 73
9.3.1.5.6 TRISOMY 18 73
9.3.1.5.7 HEMOPHILIA 73
9.3.1.5.8 TRISOMY 13 73
9.3.1.5.9 MICRODELETION SYNDROME 73
9.3.1.5.10 FETAL GENDER 73
9.3.1.5.11 OTHERS 73
9.3.1.6 BY SCREENING TYPE 74
9.3.1.6.1 CARRIER SEQUENCING 74
9.3.1.6.2 SEQUENTIAL SEQUENCING 74
9.3.2 MATERNAL SERUM QUAD SCREENING 75
9.4 NEW BORN SCREENING 75
9.4.1 SICKLE CELL DISEASE 76
9.4.2 CONGENITAL HYPOTHYROIDISM 76
9.4.3 PHENYLKETONURIA (PKU) 76
9.4.4 GALACTOSEMIA 76
9.4.5 MAPLE SYRUP URINE DISEASE 76
9.4.6 OTHERS 77
9.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 77
9.6 CARRIER TESTING 77
9.6.1 BY TEST TYPE 78
9.6.1.1 MOLECULAR SCREENING TEST 78
9.6.1.2 BIOCHEMICAL SCREENING TEST 78
9.6.2 BY TYPE 79
9.6.2.1 EXPANDED CARRIER SCREENING 79
9.6.2.1.1 PREDESIGNED PANEL TESTING 80
9.6.2.1.2 CUSTOM-MADE PANEL TESTING 80
9.6.2.2 TARGETED DISEASE CARRIER SCREENING 80
9.6.3 BY MEDICAL CONDITION 81
9.6.3.1 HEMATOLOGICAL CONDITIONS 81
9.6.3.2 PULMONARY CONDITIONS 81
9.6.3.2.1 NEUROLOGICAL CONDITIONS 81
9.6.3.2.2 OTHER CONDITIONS 81
9.7 OTHER TYPES 82
10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY 83
10.1 OVERVIEW 84
10.2 POLYMERASE CHAIN REACTION 87
10.2.1 REAL-TIME PCR (QPCR) 87
10.2.2 DIGITAL PCR (DPCR) 87
10.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 88
10.2.4 HOT-START PCR 88
10.2.5 MULTIPLEX PCR 88
10.2.6 OTHER PCR 88
10.3 DNA SEQUENCING (NGS-BASED TESTING) 88
10.3.1 NEXT GENERATION SEQUENCING (NGS) 89
10.3.2 SANGER SEQUENCING (SINGLE GENE) 89
10.3.3 OTHER 89
10.4 WHOLE GENOME SEQUENCING 89
10.5 MICROARRAYS 90
10.5.1 DNA MICROARRAYS 90
10.5.2 PROTEIN MICROARRAYS 90
10.5.3 OTHER MICROARRAYS 90
10.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 91
10.7 OTHERS 91
11 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY DISEASES 92
11.1 OVERVIEW 93
11.2 CANCER 96
11.2.1 BREAST 96
11.2.2 COLON 96
11.2.3 LUNG 96
11.2.4 PROSTATE 97
11.2.5 OTHERS 97
11.3 SICKLE CELL ANEMIA 97
11.4 THALASSEMIA 98
11.5 RARE GENETIC DISORDER 98
11.5.1 TRISOMY 21 99
11.5.2 MONOSOMY X 99
11.5.3 TRISOMY 13 99
11.5.4 MICRODELETION SYNDROME 99
11.5.5 TRISOMY 18 99
11.5.6 OTHERS 99
11.6 FRAGILE X SYNDROME 100
11.7 DUCHENNE MUSCULAR DYSTROPHY 100
11.8 HUNTINGTON'S DISEASE 100
11.9 CYSTIC FIBROSIS 101
11.10 OTHERS 101
12 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER 102
12.1 OVERVIEW 103
12.2 HOSPITALS 106
12.3 CLINICS 106
12.4 DIAGNOSTIC CENTERS 106
12.5 PRIVATE CLINICS 107
12.6 LABORATORY SERVICE PROVIDERS 107
12.7 PRIVATE LABORATORIES 108
13 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY REGION 109
13.1 OVERVIEW 110
13.2 MIDDLE EAST & AFRICA 111
13.2.1 SOUTH AFRICA 125
13.2.2 SAUDI ARABIA 134
13.2.3 U.A.E. 143
13.2.4 ISRAEL 152
13.2.5 EGYPT 161
13.2.6 REST OF MIDDLE EAST AND AFRICA 170
14 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 171
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 171
15 SWOT ANALYSIS 172
16 COMPANY PROFILE 173
16.1 ILLUMINA, INC. 173
16.1.1 COMPANY SNAPSHOT 173
16.1.2 REVENUE ANALYSIS 173
16.1.3 PRODUCT PORTFOLIO 174
16.1.4 RECENT DEVELOPMENT 174
16.1.4.1 ACQUISITION 174
16.1.4.2 COLLABORATION 174
16.2 FULGENT GENETICS 175
16.2.1 COMPANY SNAPSHOT 175
16.2.2 REVENUE ANALYSIS 175
16.3 ABBOTT 177
16.3.1 COMPANY SNAPSHOT 177
16.3.2 REVENUE ANALYSIS 177
16.5 PERKINELMER INC. 181
16.5.1 COMPANY SNAPSHOT 181
16.5.2 REVENUE ANALYSIS 181
16.5.3 PRODUCT PORTFOLIO 182
16.5.4 RECENT DEVELOPMENT 182
16.5.4.1 PRODUCT LAUNCH 182
16.6 THERMO FISHER SCIENTIFIC INC. 183
16.6.1 COMPANY SNAPSHOT 183
16.6.2 REVENUE ANALYSIS 183
16.6.3 PRODUCT PORTFOLIO 184
16.6.4 RECENT DEVELOPMENT 184
16.6.4.1 COLLABORATION 184
16.7 EUROFINS SCIENTIFIC 185
16.7.1 COMPANY SNAPSHOT 185
16.7.2 REVENUE ANALYSIS 185
16.7.3 PRODUCT PORTFOLIO 186
16.7.4 RECENT DEVELOPMENT 186
16.7.4.1 PRODUCT LAUNCH 186
16.8 MYRIAD GENETICS 187
16.8.1 COMPANY SNAPSHOT 187
16.8.2 REVENUE ANALYSIS 187
16.8.3 PRODUCT PORTFOLIO 188
16.8.4 RECENT DEVELOPMENT 188
16.9 BIOCARTIS 189
16.9.1 COMPANY SNAPSHOT 189
16.9.2 REVENUE ANALYSIS 189
16.9.3 PRODUCT PORTFOLIO 190
16.9.4 RECENT DEVELOPMENT 190
16.9.4.1 PARTNERSHIP 190
16.9.4.2 AGREEMENT 190
16.10 BIO-HELIX 191
16.10.1 COMPANY SNAPSHOT 191
16.10.2 PRODUCT PORTFOLIO 191
16.10.3 RECENT DEVELOPMENT 191
16.11 BIO-RAD LABORATORIES, INC. 192
16.11.1 COMPANY SNAPSHOT 192
16.11.2 REVENUE ANALYSIS 192
16.11.3 PRODUCT PORTFOLIO 193
16.11.4 RECENT DEVELOPMENTS 193
16.11.4.1 ACQUISITION 193
16.11.4.2 PARTNERSHIP 194
16.12 BIOREFERENCE 195
16.12.1 COMPANY SNAPSHOT 195
16.12.2 REVENUE ANALYSIS 195
16.12.3 PRODUCT PORTFOLIO 196
16.12.4 RECENT DEVELOPMENT 196
16.12.4.1 ACQUISITION 196
16.13 ELITECHGROUP 197
16.13.1 COMPANY SNAPSHOT 197
16.13.2 PRODUCT PORTFOLIO 197
16.13.3 RECENT DEVELOPMENTS 197
16.13.3.1 PRODUCT LAUNCH 197
16.13.3.2 BUSINESS EXPANSION 198
16.14 EUGENE LABS 199
16.14.1 COMPANY SNAPSHOT 199
16.14.2 PRODUCT PORTFOLIO 199
16.14.3 RECENT DEVELOPMENT 199
16.15 F. HOFFMANN-LA ROCHE LTD) 200
16.15.1 COMPANY SNAPSHOT 200
16.15.2 REVENUE ANALYSIS (PARENT COMPANY) 200
16.15.3 PRODUCT PORTFOLIO 201
16.15.4 RECENT DEVELOPMENTS 201
16.15.4.1 PRODUCT LAUNCH 201
16.16 GENES2ME 202
16.16.1 COMPANY SNAPSHOT 202
16.16.2 PRODUCT PORTFOLIO 202
16.16.3 RECENT DEVELOPMENT 202
16.17 INVITAE CORPORATION 203
16.17.1 COMPANY SNAPSHOT 203
16.17.2 REVENUE ANALYSIS 203
16.17.3 PRODUCT PORTFOLIO 204
16.17.4 RECENT DEVELOPMENTS 204
16.18 MAPMYGENOME 206
16.18.1 COMPANY SNAPSHOT 206
16.18.2 PRODUCT PORTFOLIO 206
16.18.3 RECENT DEVELOPMENT 206
16.19 MEDGENOME 207
16.19.1 COMPANY SNAPSHOT 207
16.19.2 PRODUCT PORTFOLIO 207
16.19.3 RECENT DEVELOPMENT 208
16.20 NATERA, INC. 209
16.20.1 COMPANY SNAPSHOT 209
16.20.2 PRODUCT PORTFOLIO 209
16.20.3 RECENT DEVELOPMENT 210
16.20.3.1 PARTNERSHIP 210
16.21 OTOGENETICS 211
16.21.1 COMPANY SNAPSHOT 211
16.21.2 PRODUCT PORTFOLIO 211
16.21.3 RECENT DEVELOPMENT 211
16.22 PACBIO 212
16.22.1 COMPANY SNAPSHOT 212
16.22.2 REVENUE ANALYSIS 212
16.22.3 PRODUCT PORTFOLIO 213
16.22.4 RECENT DEVELOPMENT 213
16.23 QIAGEN 214
16.23.1 COMPANY SNAPSHOT 214
16.23.2 PRODUCT PORTFOLIO 214
16.23.3 RECENT DEVELOPMENTS 215
16.23.3.1 PARTNERSHIP 215
16.23.3.2 PRODUCT LAUNCH 215
16.24 SEMA4 OPCO, INC. 216
16.24.1 COMPANY SNAPSHOT 216
16.24.2 REVENUE ANALYSIS 216
16.24.3 PRODUCT PORTFOLIO 217
16.24.4 RECENT DEVELOPMENT 217
16.25 SORENSON GENOMICS 218
16.25.1 COMPANY SNAPSHOT 218
16.25.2 PRODUCT PORTFOLIO 218
16.25.3 RECENT DEVELOPMENT 218
17 QUESTIONNAIRE 219
18 RELATED REPORTS 222
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security